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Abstract
Background: Sex chromosomal abnormalities are relatively common, yet many aspects of these syndromes remain 
unexplored. For instance epidemiological data in 47,XYY persons are still limited.
Methods: Using a national Danish registry, we identified 208 persons with 47,XYY or a compatible karyotype, whereof 
36 were deceased; all were diagnosed from 1968 to 2008. For further analyses, we identified age matched controls 
from the male background population (n = 20,078) in Statistics Denmark. We report nationwide prevalence data, data 
regarding age at diagnosis, as well as total and cause specific mortality data in these persons.
Results: The average prevalence was 14.2 47,XYY persons per 100,000, which is reduced compared to the expected 98 
per 100,000. Their median age at diagnosis was 17.1 years. We found a significantly decreased lifespan from 77.9 years 
(controls) to 67.5 years (47,XYY persons). Total mortality was significantly increased compared to controls, with a hazard 
ratio of 3.6 (2.6-5.1). Dividing the causes of deaths according to the International Classification of Diseases, we identified 
an increased hazard ratio in all informative chapters, with a significantly increased ratio in cancer, pulmonary, 
neurological and unspecified diseases, and trauma.
Conclusion: We here present national epidemiological data regarding 47,XYY syndrome, including prevalence and 
mortality data, showing a significantly delay to diagnosis, reduced life expectancy and an increased total and cause 
specific mortality.
Background
One of the first descriptions of 47,XYY is from 1965 by
J a c o b s  e t  a l  [ 1 ] .  H e r e  a  c h r o m o s o m e  s u r v e y  o f  m a l e
patients at the State Hospital in Carstairs was conducted.
The hypothesis being that 47,XYY was particularly fre-
quent among inmates in penal institutions. Later, other
studies took place in hospitals among consecutively born
babies [2-7] using techniques enabling the identification
of extra Y chromosome material. These studies identified
highly variable number of 47,XYY  persons, ranging in
liveborn from 26 per 100,000 [2] to 375 per 100,000 [4].
We calculated the prevalence of 47,XYY at birth by pool-
ing data from the surveys in consecutively liveborn babies
in various countries and estimated the prevalence of
47,XYY to 98 per 100,000 (95% CI: 73-129) (51 47,XYY
persons out of 52,004 liveborn boys). A few earlier chro-
mosomal studies only used identification of Barr bodies,
for instance from smears from the oral mucosa, hence no
Y chromosome defects were identified [8,9]. By compari-
son, it is estimated that sex chromosomal abnormalities
occur in 1 per 400 births [10].
Only limited data regarding age at diagnosis in 47,XYY
syndrome in a relatively unselected population are avail-
able [11]. To date, not much is generally known regarding
clinical phenotype of individuals with 47,XYY, except tall
stature [12], possibly due to the expression of three copies
of the short statue homeobox-containing gene (SHOX),
which is located on the distal ends of Xp and Yp in the
pseudoautosomal region 1 (PAR1) [13].
One British study [14] identified a significantly
increased mortality in total and in diseases of the respira-
tory system in a 47,XYY  population compared to the
background population. However, to our knowledge
nothing is known concerning prevalence and mortality in
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a nationwide identified 47,XYY population. We therefore
undertook the present Danish nationwide study, investi-
gating age at diagnosis, prevalence and mortality in a
cohort of 47, XYY persons and comparing this to a large
background population.
Identification of 47,XYY persons
The Danish Cytogenetic Central Registry was founded in
1967 and contains all national data regarding the diagno-
ses of chromosomal anomalies, including information
from the years before 1967. The first diagnosis of 47,XYY
in Denmark was in 1965. We retrieved the identification
(ID) number of all Danish men ever diagnosed with
47,XYY in Denmark, referred to here as index-persons.
As an index-person we accepted variants of 47,XYY
including mosaics (46,XY/47,XYY). Due to their more
severe phenotype 48,XXYY males (n = 23) and 48,XYYY
males (n = 1) were not included as well as 47,XYY males
with an autosomal aneuploidy (n = 1), as their sex chro-
mosomal aneuploidy was considered of minor impor-
tance. Hereby 208 index-persons were identified, for
details see table 1. It is important to emphasize that no
information regarding phenotype or reasons for which
the chromosomal analyses were performed were included
in the registry. In 1968 and onwards, one unique ID-num-
ber was allocated to every living Dane. Date of birth and
gender can easily be identified using the ID-number. The
ID-numbers as well as date of diagnosis were retrieved
from the Danish Cytogenetic Central Registry in March
2009.
Identification of controls
Statistics Denmark was founded in 1850, and contains
numerous statistics regarding Denmark and Danes. Using
the ID-number, Statistics Denmark http://www.dst.dk
identified for each index-person up to 100 controls from
the male background population, matched on age (year
and month of birth). All controls were alive and living in
Denmark on the date their index-person was diagnosed
with 47,XYY. For two index-persons the matching was
not undertaken for unknown reasons, and mortality data
are therefore on 206 47,XYY persons. Furthermore, we
retrieved data regarding date of emigration, date of death,
and up to three causes of death on these men. None were
lost to follow-up.
Mortality
All controls were alive and registered in Denmark on the
day the index-person was diagnosed with 47,XYY. Mor-
tality data was updated with 31st of December 2008 being
the last date of death registered, whereas causes of death
were updated until 31st of December 2006. Thus, all who
were deceased in 2007 and 2008 were registered with date
of death, but without registration of causes of death.
The causes of death were given in International Classi-
fication of Diseases (ICD) 8th edition until 1993, and in
ICD-10 and onwards. We translated ICD-8 diagnoses to
ICD-10, and divided all deaths into 19 chapters according
to ICD-10 for analysis of cause-specific mortality. Cause-
specific mortality hazard ratios (HR) were calculated for
each of the 19 chapters in ICD-10, as well as in total.
Table 1: Details regarding the karyotypes
Subgroup Specific karyotype Number
47,XYY 47,XYY
47,XYY,inv(9)
Subtotal
175
2
177
46,XY/47,XYY 46,XY/47,XYY
45,X/46,XY/47,XYY
45,X/47,XYY
Subtotal
20
1
1
22
Others 47,XY,?YQ-
47,XYY/48,XXYY
47,XY,r(Y)(P11Q11)
45,X/46,X,idic(Y)(P11.3)/47,X,idic(Y)(P11.3)
47,XYY,inv(5)(P13.3P15.33)
46,XY,t(9;19)(Q21;Q13)/47,XYY,t(9;19)(Q21;Q13)
46,XY/47,XY,+I(YQ) 45,X/45,Y/46,XY/47,XYY
Subtotal
2
1
1
1
1
1
1
1
9
Total 208
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Statistics
The calculation of the expected prevalence was per-
formed by adding all 47,XYY persons or variants identi-
fied in screening studies as well as the number of liveborn
boys investigated. The confidence intervals were calcu-
lated using the poisson distribution.
To compare median age at diagnosis, median date of
birth and median date of diagnosis in the three sub-
groups, we used the Kruskal-Wallis test. The time trend
in age at diagnosis was analyzed using linear regression.
The prevalence was calculated as number of diagnoses
per 100 000 liveborn boys in the background population
p e r  y e a r  o f  d i a g n o s i s .  C o n f i d e n c e  i n t e r v a l s  w e r e  e s t i -
mated using an approximation to the Poisson distribu-
t i o n .  T h e  s p e c i f i c  n u m b e r s  o f  l i v e b o r n  b o y s  i n  t h e
background population were obtained using Statistics
Denmark. To identify changes in prevalence per year of
diagnosis we used Poisson regression. The average preva-
lence was calculated as average number of incident
47,XYY persons during 1970-2008 divided by the average
number of liveborn boys in the background population
during the same period. This study period was applied to
ensure enough run-in time in the Danish Cytogenetic
Registry from time of establishment.
Mortality was described with Kaplan-Meier survival
estimates constructed using date of birth as entry. Date of
emigration, date of death or 31st  of December 2008,
whichever came first, were used as date of exit. For com-
parison log-rank analysis was applied.
HRs were calculated using Cox regression analysis with
stratification, using each person and his matched controls
as a stratum. Hereby, comparisons were adjusted for age
and calendar time, and calculation of expected number of
deaths was possible. Time at risk was calculated as time
from date of diagnosis until date of emigration, date of
death or 31st of December 2008, whichever came first,
this applied to both index-persons and controls. All
results are shown with 95% confidence intervals, or with
range if relevant, and p < 0.05 was considered statistically
significant. We made no formal corrections for multiple
comparisons. We used Stata 10.0 (Stata Corp. College
Station,TX, USA) for all calculations.
Results
In the Danish Cytogenetic Central Registry we identified
208 males diagnosed between 1965 and 2008 with
47,XYY or a compatible karyotype and divided them into
three subgroups (Table 1). Age at diagnosis, year of birth
and year of diagnosis is seen in Table 2. The vast majority
(n = 177) were non-mosaic 47,XYY. In all three subgroups
age at diagnosis had a wide range, spanning more than 65
years. The subgroup of "Others" (n = 9) were both signifi-
cantly older than the other two subgroups at diagnosis
(both p < 0.05), as well as born significantly earlier in the
study period (both p < 0.05). In the total cohort, age at
diagnosis significantly decreased during the study period
(p < 0.05, Figure 1), as in the mosaic subgroup (p < 0.05).
The distribution of age at diagnosis is seen in Figure 2.
Twenty-five percent were diagnosed within the age of 5.9
years, 50% with the age of 17.1 years, and 75% within the
age of 28.0 years.
During 1970-2008 we identified 180 47,XYY persons,
corresponding to an average of 4.6 persons yearly. With
an average of 32 794 liveborn boys in Denmark we thus
identified 14.1 47,XYY persons per 100 000 liveborn.
Prevalence per 100 000 liveborn boys in the background
population were stable during the study period (p = 0.96)
(Figure 3), however there seemed to be an increase from
1995 until 2008.
In Statistics Denmark we identified 20 078 matched
controls; a minimum of 82 controls were identified per
index-person. During the study period 1 895 controls and
36 index-persons died, whereof ten deaths were expected.
Twenty-eight index-persons died in the 47,XYY sub-
group, four in the mosaic subgroup and four in the sub-
group of others. Mortality was significantly increased in
47,XYY persons in total (p < 0.0001) (Figure 4) and in all
three subgroups (all p < 0.0005). Time at risk, corre-
sponding to time from date of diagnosis to date of exit,
was 3 373 years in the index-persons and 373 946 years in
the controls. The median age of survival was 77.9 years
for controls and 67.5 years for 47,XYY persons, corre-
sponding to a loss of median lifespan of 10.3 years.
Due to date of death in 2007 or later, the causes of
deaths were not available in one 47,XYY person and in
187 controls. For another ten controls the date of death
was before 2007 and without known cause of death.
These ten deaths were only included in the analysis of
total mortality. Using Cox regression we identified a sig-
nificantly increased total mortality, with a HR of 3.6 (2.6-
5.1). The HRs of all informative chapters (corresponding
to chapters with at least one deceased person and one
deceased control) are shown in Figure 5.
Discussion
Nationwide we have identified all males diagnosed with a
diagnosis compatible with 47,XYY and identified a signif-
icantly increased total mortality. Generally, cause specific
mortality was increased compared to age and gender
matched controls. Mortality data have to our knowledge
not before been reported in a nationwide cohort with this
specific karyotype. Our finding of a total mortality ratio
of 3.6 is in comparison or even more pronounced than
findings in Turner Syndrome [15,16] or Klinefelter Syn-
drome [17] or 47,XXX [18] and also higher than found in
the only other study in a 47,XYY cohort by Swerdlow et al
[14] with a relative risk of 1.9 (1.20-2.85), although with
overlapping confidence interval. The reduction ofStochholm et al. Orphanet Journal of Rare Diseases 2010, 5:15
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lifespan of 10.3 years is even more than the expected loss
of median lifespan in heavy smokers compared to non-
smokers in Denmark [19]. In addition, we demonstrate a
considerable delay in diagnosis and a low prevalence of
47,XYY.
In all informative chapters cause specific mortality was
generally increased. Analyzing the chapters separately, we
identified a significantly increased mortality in cancer,
neurological, and pulmonary diseases, trauma and the
chapter of unspecified diseases. Further, we identified a
statistically significant HR in the chapters concerning the
skin, urological diseases, and chromosomal disorders.
These analyses are compromised by a small number of
deaths among the 47,XYY persons (n = 1), and we con-
sider the significant HR in these three chapters as a
chance finding, however in line with the generally
increased mortality. The British data showed a signifi-
cantly increased mortality in pulmonary diseases only
[14]. Time at risk is comparable in the British study (3 174
years) and the present one (3 373 years), but the distribu-
tion of age at diagnosis cannot readily be extracted from
the former study. However, our exact matching of index-
persons and controls is methodologically superior. If a
similar approach was possible in the British study, proba-
bly further significant chapters would have been identi-
fied.
We have no obvious explanation for the finding of sig-
nificantly increased mortality in the various ICD-10
chapters. However, it is noteworthy that the HR of the
cardiovascular diseases reached 2.2 (0.99-5.04), p = 0.05,
and was as such not significant. We presume that an
increased number of index-persons or increased time of
observation would have identified a significant HR here
as well. It is important to note the total number of deaths
Table 2: Details regarding 47,XYY persons.
Karyotype Number of persons Median age at 
diagnosis (range)
Median year of birth 
(range)
Median year of 
diagnosis (range)
47,XYY 177 16.9
(0.0-67.1)
1971.9
(1909.4-2007.3)
1988.1
(1965.7-2008.9)
46,XY/47,XYY 22 6.9
(0.0-70.7)
1983.9
(1899.8-2007.6)
1996.3
(1968.9-2007.6)
Others 9 28.8 1)
(0.0-66.5)
1948.6
(1910.9-1984.5)
1977.5 1)
(1969.1-2006.2)
Total 208 17.1
(0.0-70.7)
1972.4
(1899.8-2007.6)
1988.2
(1965.7-2008.9)
Details regarding all men diagnosed with a karyotype compatible with 47,XYY in Denmark between 1965 to 2008.
1)p-value < 0.05 compared to both of the other subgroups.
Figure 1 Age at diagnosis in all males diagnosed in Denmark with 
47,XYY during 1965 to 2008.
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in the chapters and not only the significance level. When
few deaths among 47,XYY persons are registered, esti-
mates of hazard ratio have a wide confidence interval and
hence are relatively imprecise. Due to the limited number
of deaths, we have not undertaken analyses regarding
eventual sub grouping in any of the chapters, apart from
the trauma chapter. Due to the early reports regarding
47,XYY males being overrepresented in prisons [20,21]
we scrutinized data in the trauma chapter. Here, a total of
five 47,XYY persons and 176 controls died. The deaths in
the  47,XYY  persons were due to suicide in an oligo-
phrenic person (n = 1), traffic accident (a pedestrian
addicted to drugs) (n = 1), various somatic lesions due to
foreign body in the gastro-intestinal system (n = 1), due
to overdose with tricyclic antidepressive (n = 1) and a
subarachnoid hemorrhage whilst abusing heroin (n = 1).
It is important to note that three of these deaths include
either an overdose or drug abuse. We recommend that
the possibility of a diagnosis of 47,XYY is considered in
drug addicted men who are tall [22,23] or have other stig-
mata.
The average prevalence of 14.1 per 100 000 is lower
than the expected prevalence of 98 in 100 000, however
higher than the finding by Abramsky et al in a smaller
study from three English laboratories [11]. Here 5.3 per-
cent of the estimated number of 47,XYY persons were
identified. In the study by Abramsky at al., six 47,XYY
persons were younger and five older than 20 years at
diagnosis, which we consider comparable with our find-
ing of a median age at diagnosis of 17.1 years. Only very
large scale studies of huge populations will be sufficient
to fully establish the exact prevalence of 47,XYY.
The reduction of age at diagnosis during the study
period may signal an increased awareness of 47,XYY
among physicians. Males identified in a clinical setting
are not comparable to those identified in surveys, basi-
cally due to the presumed highly variable phenotype
among 47,XYY persons spanning from a normal pheno-
type to a clearly abnormal phenotype. Thus, males identi-
fied using our approach of focusing only on all persons
diagnosed naturally bias the results. However, for the
time being there is no other possible way of identifying
Figure 3 Prevalence rate of 47,XYY males in Denmark during 
1970 to 2008. The number of diagnosed 47,XYY males in Denmark 
during 1970-2008 per 100,000 liveborn boys per year of diagnosis.
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Figure 4 Kaplan-Meier survival graphs in 47,XYY compared to an 
age-matched male background population. Time at risk was calcu-
lated from date of birth until date of censoring (see Materials and 
Methods for details). Solid line controls, and thin line persons. Survival 
is significantly lower in 47,XYY persons, log-rank p < 0.0001. Number of 
persons and controls are indicated below the figure.
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Figure 5 Hazard ratios of total and cause specific mortality in 
47,XYY compared to age-matched males. Time at risk was calculat-
ed from date of diagnosis until date of censoring (see Materials and 
Methods for details). The causes are divided in nineteen chapters ac-
cording to the International Classification of Diseases. Only informative 
chapters are included.
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the remaining undiagnosed males nationwide, and, more
importantly, it is the persons diagnosed that we see in the
daily clinic, or who themselves know that they have this
chromosomal abnormality. It is important to emphasize
that this report only includes males diagnosed with this
karyotype. Thus, we consider this cohort as representa-
tive of the 47,XYY males being seen by clinicians at the
current point of time. To which degree the fact that only a
limited percentage of the 47,XYY persons are identified,
influences the increased mortality is not known. How-
ever , we expect that inclusion of more 47,XYY persons,
possibly less stigmatized, will tend to reduce the
increased mortality found in the present study.
I n  c o n c l u s i o n ,  i n  t h is  fi r s t  n a t i o n wi d e  s t u d y  i n  d i a g -
nosed  47,XYY  persons we have identified an average
prevalence of 14.1 per 100 000, which is lower than the
expected of 98 per 100 000. The 47,XYY persons are diag-
nosed relatively late with a median age at diagnosis of
17.1 years. Their total mortality is significantly increased
compared to age and gender matched controls from the
background population. Furthermore, this increased
mortality is present in all informative chapters according
to the ICD-10 and significantly increased in the follow-
ing: cancer, neurological, and pulmonary diseases,
trauma and the chapter of unspecified diseases. Much
more needs to be learned about this syndrome and clini-
cal studies should be conducted in order to identify clini-
cal problems enabling future decrease in the increased
risk of death.
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